Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Stifel Virtual Healthcare Conference Transcript

Nov 17, 2020 / 07:00PM GMT
Release Date Price: $77.4
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks very much, everybody. Happy to be here on this panel for the next 30 minutes with the BioMarin management team.

With me is Brian Mueller, who's the Executive Vice President and CFO; and also Hank Fuchs, who is the President of Worldwide R&D. I'm sure most people listening here know the team quite well.

I think we're just going to start and have Brian make some introductory remarks on the recent BioMarin quarter and a few pipelines updates and than we will get into Q&A.

So, Brian, thank you, again, and please take it away.

Brian R. Mueller
BioMarin Pharmaceutical Inc. - Executive VP & CFO

Hi, everybody. Thank you, Paul, really appreciate the opportunity to participate today. As you know, we recently shared our third quarter 2020 results where we provided a number of updates.

On the financials, we tightened our GAAP net income guidance and improved our non

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot